Grants of Research Licenses. 5.2.1 Abgenix and Pfizer each grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, to make and use Confidential Information, Joint Technology and joint Patent Rights for all research purposes other than the sale or manufacture for sale of products or processes except for the following:
(i) this license does not include the Xenomouse(TM) animals owned by Abgenix; and
Grants of Research Licenses. Myco and Pfizer each grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, (i) to make and use Confidential Information, Technology and Patent Rights for all research purposes under the Research Program and (ii) to make and use Confidential Information, Technology and Patent Rights other than culture collections and other drug sources and screens or screening systems for research purposes ******* ***** other than (a) for purposes of ********** ********* and (b) the ************ ********.
Grants of Research Licenses. Helicon and Roche each grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to
Grants of Research Licenses. 5.2.1 Medarex and Pfizer each grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, to make and use the other party’s Technology and Confidential Information for all research purposes other than the sale or manufacture for sale of products or processes except that this license does not include the Additional Technology, the HuMAb Mice, the Additional Mice or other human antibody transgenic animals owned by Medarex or Mice Materials related thereto.
5.2.2 Medarex grants to Pfizer a co-exclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, to make and use Antibody Materials for Pfizer’s own research purposes other than the sale or manufacture for sale of products or processes, provided that such license shall not include any rights to Antibody Materials that are derived from the Additional Technology, the Additional Mice or Mice Materials related thereto.
Grants of Research Licenses. Gensia and Pfizer each grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, to make and use Confidential Information, Technology and Patent Rights for all research purposes other than the sale or manufacture for sale of
Grants of Research Licenses. Icagen and Pfizer each grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, (a) under Patent Rights and Technology Controlled by such party to make and use Compounds developed in or introduced into the Research Program solely for research purposes, and (b) under Patent Rights and Technology Controlled by such party and Developed In The Research Program solely for research purposes. For clarity, this Section 3.2 does not grant either party any right or license under or with respect to Patent Rights or Technology Controlled by the other party to develop, sell or manufacture for sale any Compound or Technology.
Grants of Research Licenses. Megabios and Pfizer each grants to --------------------------- the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, to make and use Confidential Information, Technology and Patent Rights (other than that pertaining to DNA Manufacture) for all research purposes other than the sale or manufacture for sale of products or processes.
Grants of Research Licenses. 14.3.1 Subject to the terms and conditions of this Agreement: i), [ *** ] grants to [ *** ] a [ *** ], [ *** ], to [ *** ] to the extent necessary to allow [ *** ] [ *** ] and any other [ *** ] of the [ *** ] by [ *** ] pursuant to the [ *** ] or [ *** ] as it sees fit in its course of business, including [ *** ]; and, ii) [ *** ] grants to [ *** ] a [ *** ], to [ *** ] that is provided to [ *** ] in connection with the [ *** ] to the extent such [ *** ] are necessary to allow [ *** ].
14.3.2 [ *** ] grants to [ *** ] a [ *** ] solely relating to [ *** ].
Grants of Research Licenses. OSI, MRC CC and SANKYO each grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates, to make and use its Technology Improvements for all research purposes other than the sale or manufacture for sale of products or processes.
Grants of Research Licenses. (a) Millennium and Pfizer each hereby grants to the other a nonexclusive, irrevocable, worldwide, royalty-free, perpetual license, including the right to grant sublicenses to Affiliates to make and use Confidential Information, Program Technology and Patent Rights for all research purposes.
(b) During the exclusivity Period, Pfizer shall have the exclusive right to seek Products based on the Program Technology.
(c) Notwithstanding the provisions of Subsection 5.2(b), if during the exclusivity Period Pfizer withdraws its medicinal chemistry program associated with the [**], Pfizer shall so notify Millennium in writing and Millennium shall then have the right, exercisable within 90 days of such notice, to obtain from Pfizer (1) an exclusive royalty-fee research license for the [**] to discover Products (the "NMT Research License"); (2) subject to Pfizer's exclusive reservation set forth in Section 2.2 of the License Agreement, an exclusive, royalty-bearing, worldwide license to make, use, sell, offer for sale and import Products discovered using the NMT Research License (the "NMT Commercial License"); (3) copies of, and the right to use under the NMT Research License, Pfizer Confidential Information relating to the NMT program and (4) up to six different samples, each of 50 milligrams, selected by Millennium from among the analogues prepared by Pfizer in the course of its medicinal chemistry program associated with the [**], to the extent such samples are then available. Pfizer shall be under no obligation to re-synthesize any compounds in order to provide Millennium with such samples." Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
1.8 Section 5.4 is hereby amended to add the following phrase before the first sentence of the existing text "Subject to the obligations to pay royalties on products set forth in Section 3.2 of the License Agreement". Further, Section 5.4 is hereby amended so that the term "Program Technology" replaces the term "Joint Technology" wherever the latter appears, and so that the term "Patent Rights" replaces the term "Joint Patent Rights" wherever the latter appears.
